Conjunctivitis Does Not Increase With Longer Duration of Lebrikizumab Exposure in Patients With Moderate-to-Severe Atopic Dermatitis

Main Article Content

April Armstrong
University of California Los Angeles (UCLA), Los Angeles, USA

Andreas Wollenberg
Augsburg University Hospital, Augsburg, Germany and Ludwig-Maximilian University, Munich, Germany

Marjolein de Bruin-Weller
University Medical Center Utrecht, The Netherlands

Peter A. Lio
Northwestern University Feinberg School of Medicine, Chicago, USA

Chitra R. Natalie
Eli Lilly and Company, Indianapolis, USA

Fangyi Zhao
Eli Lilly and Company, Indianapolis, USA

Amber Reck Atwater
Eli Lilly and Company, Indianapolis, USA

Gemma Jimenez
Almirall, S.A., Barcelona, Spain

Chia-Yu Chu
National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan

Christian Vestergaard
University of Aarhus, Aarhus, Denmark

Keywords

Lebrikizumab, conjunctivitis, atopic dermatitis

References

1. Grant L, et al. Dermatitis. 2019;30:247-254.

2. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547.

3. Ratnarajah K, et al. J Cutan Med Surg. 2021;25:315-328.

4. Guttman-Yassky E, et al. JAMA Dermatol. 2020;156:411-420.

5. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091.

6. Simpson EL, et al. JAMA Dermatol. 2023;159:182-191.

7. Stein Gold L, et al. Am J Clin Dermatol. 2023;24:595-607.

Article Sidebar

PDF
Published
Nov 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.276

Article Details

How to Cite
Armstrong, A. ., Wollenberg, A. ., de Bruin-Weller, M. ., Lio, P. A. ., Natalie, C. R. ., Zhao, F. ., Reck Atwater, A. ., Jimenez, G. ., Chu, C.-Y. ., & Vestergaard, C. . (2023). Conjunctivitis Does Not Increase With Longer Duration of Lebrikizumab Exposure in Patients With Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine, 7(6), s276. https://doi.org/10.25251/skin.7.supp.276
Issue
Vol. 7 No. 6 (2023): November 2023 Issue
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 > >>